Jiangsu Hengrui Pharmaceuticals (01276): Injection SHR-9839 (sc) and injection HRS-4642 approved for drug clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, the company and its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injection SHR-9839(sc) and HRS-4642 injection. The clinical trials will be conducted soon. SHR-9839 is a humanized antibody drug independently developed by the company, intended for the treatment of advanced solid tumors by simultaneously blocking two key signaling pathways related to tumor development, exerting an anti-tumor effect. Injection SHR-9839(sc) is a subcutaneous injection preparation of SHR-9839, and currently, there is one drug with the same target approved and on the market globally. HRS-4642 injection is a lipid-based formulation of the company's independently developed KRAS G12D inhibitor. HRS-4642 injection specifically binds to KRAS G12D, inhibiting the phosphorylation of MEK and ERK proteins, exerting an anti-tumor effect. Currently, there are no similar drugs approved and on the market domestically or internationally.